戻る Agenda
[Session 2]Clinical / ECG
Session Chair(s)
Atsushi Sugiyama, MD, PHD
Professor and Chairman, Department of Pharmacology, Toho University Faculty of Medicine, Japan
Kyosuke Takeshita, MD, PHD
Department of Clinical Laboratory Medicine, Saitama Medical Center, Saitama Medical University, Japan
Speaker(s)
Börje C. Darpö, MD, PHD
Chief Scientific Officer, Cardiac Safety, Clario, Sweden
Replacing the Thorough QT study with Concentration-QTc analysis applied to First-in-Human studies – recent trends and experience from interactions with regulators
Kaori Shinagawa, MD, PHD
Senior Scientist for Clinical Medicine, Office of New Drug II, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Current status and future perspective of clinical proarrhythmic risk assessment from a regulatory point of view
Jorg Taubel, MD, FFPM
Chief Executive Officer, Richmond Pharmacology, United Kingdom
Reasons why it is difficult to evaluate cardiac safety for antidiabetic drugs - Findings obtained in a type 1 diabetes study examining the effects of diet on normal and insulin-deficient subjects
Boaz Mendzelevski, MD
Consultant Cardiologist, Cardiac Safety Consultants Ltd., United Kingdom